SCWorx Corp. (WORX) 株式分析

企業概要

SCWorx Corp. is a specialized entity within the healthcare sector that focuses on Health Information Services, providing data content and essential services related to the repair, normalization, and interoperability of information for healthcare providers in the United States. The company develops and markets healthcare information technology solutions along with associated services to facilitate better data management within the medical field. This small-cap enterprise operates with a market capitalization of 189 万ドル (1.89M 米ドル) and reported annual revenue (TTM) of 288 万ドル (2.88M 米ドル), while the specific number of employees is not disclosed in public records. The relatively modest market cap and revenue figures indicate that the company holds a minor position in the broader healthcare technology landscape, suggesting it is a micro-cap stock where the market values the firm at a scale significantly below large-cap peers, which often carry more established market dominance and diversified revenue streams.

財務健全性

The company reported revenue of 288 万ドル (2.88M 米ドル) over the trailing twelve months, yet generated a net loss of 4,444,109 ドル (-4,444,109 米ドル) and an EBITDA of -958,315 ドル (-958,315 米ドル). The substantial gap between positive revenue and significant negative net income reveals a cost structure where operating expenses, likely driven by the high costs of developing and maintaining healthcare information technology solutions, far exceed the gross profit generated from sales. Free cash flow stood at -814,822 ドル (-814,822 米ドル), indicating that the company is currently burning cash, which implies limited financial flexibility to fund operations without external financing or asset liquidation without incurring further dilution. The gross margin is 32.0%, suggesting a moderate ability to control the cost of goods sold, whereas the operating margin of -25.0% and profit margin of -154.4% highlight severe inefficiencies in covering overhead costs relative to sales and a net loss that exceeds total revenue due to non-operating factors. In terms of liquidity and leverage, the company holds cash of 164 万ドル (1.64M 米ドル) against total debt of 151,377 ドル (151,377 米ドル), resulting in a debt-to-equity ratio of 2.12, which indicates a highly leveraged balance sheet where debt obligations are more than twice the equity base. Despite the high debt load, the current ratio of 2.72 suggests that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity management. Furthermore, the return on equity is -76.3% and the return on assets is -8.4%, metrics that reveal that management has not been effective in generating positive returns on the capital invested by shareholders or utilized in the asset base, reflecting the ongoing challenges of the company's financial performance.

バリュエーション評価

The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, which implies that traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory at this time. The price-to-book ratio is 0.23, indicating that the market values the company at less than one-third of its book value, which suggests the market may be pricing in significant risk or expecting future value destruction rather than a market premium over book value. Alternative valuation metrics such as the price-to-sales ratio of 0.66 and the EV/EBITDA of -0.42 suggest that the company is trading at a discount relative to sales but carries negative enterprise value multiples reflecting its lack of profitability. The 52-week high is 1.37 ドル (1.37 米ドル) and the 52-week low is 0.11 ドル (0.11 米ドル), meaning the stock price has experienced extreme volatility within a range of over 1000%, and any current trading price sits somewhere within this highly compressed band relative to the full historical range. The beta value of 2.26 indicates that the stock price is significantly more volatile than the broader market, moving with an amplified intensity that exposes investors to heightened risk during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year stands at 13.8%, demonstrating top-line expansion, while earnings growth is N/A because the company is currently unprofitable, implying that revenue growth is not yet translating into bottom-line profitability and that earnings are growing slower than revenue (effectively declining from a loss perspective). As the company does not pay dividends, the dividend yield and payout ratio are both N/A, meaning there is no cash distribution to shareholders and the payout ratio of 0.0% reflects the absence of earnings to distribute rather than a sustainable dividend policy. Consequently, the company reinvests all available cash flow, which is currently negative, back into operations and technology development rather than paying dividends to shareholders. The overall growth and income profile is characterized by positive revenue expansion coupled with significant losses and no dividend income, presenting a high-risk, high-volatility equity profile typical of early-stage or turnaround companies in the healthcare technology sector.